Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From 2seventy bio, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Week in Review: VectorBuilder Raises $57 Million for Gene Therapy Delivery CDMO ↗
Via Talk Markets
News headline image
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy ↗
 
Via Benzinga
News headline image
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
The Top E-Commerce Company to Buy for Summer 2022 ↗
There's definitely a chance that struggling RealReal simply goes bankrupt, but its network effects could make it a buyout target. 
Via InvestorPlace
News headline image
The 5 Top Profit & Protection Stocks to Buy for 2022 ↗
It's important to know which quantitative factors make a stock worthwhile. These five have the attributes needed for success. 
Via InvestorPlace
News headline image
2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 951 companies hit new 52-week lows. 
Via Benzinga
News headline image
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in CG Horizons in Oncology Virtual Conference
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Secures $170 Million in Private Placement Equity Financing
From 2seventy bio, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a... 
Via Benzinga
News headline image
2seventy bio Announces Key Management Appointments
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Healthcare Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Oncternal Therapeutics (NASDAQ:ONCT 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers iSpecimen (NASDAQ:ISPC) shares rose 19.8% to $8.18 during Thursday's pre-market session. The market value of their outstanding shares is at $71.4 million. VYNE... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.